Agonist
Back to library
CognitiveOral

Trofinetide

Also known as: NNZ-2566 · Daybue · Glypromate analog

Synthetic tripeptide analog of glycine-proline-glutamate (GPE), the N-terminal fragment of IGF-1. FDA-approved (Daybue) for Rett syndrome. Modulates microglial activation, restores dendritic spine density, and normalizes synaptic function in disease models.

At a glance

Half-life
1.5 hours
Common route
Oral
Typical dose range
5,000,000–12,000,000mcg
Stability (reconstituted)
90days refrigerated

Best timing

Oral solution twice daily with food. Weight-based dosing in the approved Rett syndrome population (5–12 g/day).

Contraindications

  • Pregnancy
  • Severe diarrhea or volume depletion
  • Hypersensitivity

Watch symptoms

  • Diarrhea (very common — major dose-limiting effect)
  • Vomiting
  • Weight loss in some patients
  • Dehydration risk if diarrhea unmanaged
  • Mood or sleep changes

Citations

The primary literature.

  1. 01Trofinetide for Rett syndrome (LAVENDER Phase 3)PubMed
  2. 02NNZ-2566, a glypromate analog, mechanism and translational developmentPubMed
Back to library